Home
Storia in 1 fonti
Roche wants the best of both worlds with amylin-incretin combo strategy
Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly successful product if they act synergistically.
Raccontata da
endpoints.news
Timeline cronologica
- ·
Roche’s incretin shot works in mid-stage trial in type 1 diabetes
Roche's acmopatide cut A1C by 0.34% and reduced insulin use by 15% in a Phase 2 trial in type 1 diabetes patients with obesity.
- ·
Roche wants the best of both worlds with amylin-incretin combo strategy
Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in efficacy. Combining them could produce a highly…
- ·
AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push
AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.